Want to see OTF full AI Analyst Report?
Blue Owl Technology Finance Corp. (OTF) Q2 2026 Earnings Report
OTF Q2 2026 EPS Results
- Actual EPS
- $0.30
- Consensus EPS
- $0.30
- Beat/Miss
- Beat by +$0.00
- One Year Ago EPS
- $0.34
OTF Q2 2026 Revenue Results
- Actual Revenue
- $321.66M
- Expected Revenue
- $336.93M
- Beat/Miss
- Missed by -$15.27M
- YoY Revenue Growth
- +4.65%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/05/2026
- Time
- After Close
- Conference Call
- Wednesday, August 5, 2026
Blue Owl Technology Finance Corp.'s next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call emphasized multiple substantive strengths: stable NAV, very low nonaccruals (10 bps), improving earnings momentum (adjusted NII $0.30), strong liquidity (> $2 billion cash/capacity), constructive financing actions (issued $500M unsecured bond, $150M secured facility, revolver extended), active share repurchases (~$55M this quarter) and a clear path to cover the base dividend by mid next year. Management also highlighted attractive deployment opportunities from wider spreads and higher forward rates, plus niche growth in life sciences and digital infrastructure. Headwinds include a large and persistent market valuation discount, muted primary deal flow (especially in software), slower repayments, and ongoing AI-related uncertainty in parts of the market. On balance, the positive operational, credit and liquidity indicators materially outweigh the external valuation and market-technical challenges described by management.
Management guided that OTF expects to cover its $0.35 quarterly base dividend by mid‑2027, noting Q2 adjusted NII of $0.30 and a Q3 dividend of $0.35 plus a $0.05 special (total $0.40) supported by $0.32 of spillover gains; they plan to grow earnings by moving net leverage up from 0.93x (about +0.4 turns since the June 2025 listing and at the low end of a 0.9–1.25x target) toward the midpoint while rotating ~7% of non‑income equity into income assets. Recent activity to support that path included ~ $850M of new commitments and $550M funded (>$475M net funded), ~$222M of sales/repayments, $55M of share repurchases in the quarter (≈$170M over 3 quarters; ~$195M remaining of a $300M program), issuance of a $500M unsecured bond, $150M of secured financing, an amend/extend of a $2.7B revolver, and >$2B of cash/available capacity; portfolio metrics cited were NAV $16.48, nonaccruals $20M (10 bps), weighted‑avg EBITDA ~ $300M, software ~70% of the book, life sciences ~2%, weighted‑avg LTV ~40%, revolver utilization ~10%, PIK income ~12.5% of investment income (7.5% interest, 5% dividends, ~98% structured at origination), and roughly $4.7B of loans currently below S+500 that could be repriced into higher spreads.
- Adjusted Net Investment Income and DividendsAdjusted net investment income (adjusted NII) of $0.30 per share in Q2. Board declared Q3 base dividend of $0.35 and a final quarterly special dividend of $0.05, bringing total dividends to $0.40 per share for the quarter. Management expects to cover the base dividend by the middle of next year.
- Stable NAV and Share RepurchasesNet asset value (NAV) per share of $16.48 at quarter end, described as stable. Repurchased over $55 million of stock during the quarter and roughly $170 million over the past three quarters; ~$195 million remains available under the $300 million repurchase program.
- Strong Credit QualityNonaccruals remain low at just 10 basis points (~$20 million) of the portfolio. Weighted average borrower EBITDA near $300 million, weighted average LTV steady at 40%, revolver utilization ~10%. Internal 3–5 rated names fell modestly from 8.5% to 7.6% of fair value (down 0.9 percentage points). PIK income declined from 13.1% to ~12.5% of total investment income (down 0.6 percentage points), with ~98% of PIK structured at origination.
- Balance Sheet Strength and LiquiditySignificant financing actions completed: issued a $500 million unsecured bond, added $150 million secured financing, and amended/extended a $2.7 billion revolver with all 2026 maturities addressed. All bank partners renewed commitments; added a new lending relationship. Ended the quarter with over $2 billion of cash and available capacity across credit facilities; investment-grade ratings affirmed.
- Deployment Momentum and Portfolio ActivityApproximately $850 million of new commitments and $550 million funded during the quarter; net funded investment activity > $475 million. Received ~$222 million in sales and repayments. Net leverage finished at 0.93x (target range 0.9–1.25x) and has increased ~0.4 turns since the June 2025 direct listing, positioning the fund to deploy additional capital as opportunities arise.
- Sector Positioning and Growth OpportunitiesSoftware remains ~70% of the portfolio, concentrated in durable, mission-critical segments. Life sciences has grown to nearly 2% of the portfolio (example: Blue Owl-led $700 million platform loan for Caris). Management highlights attractive opportunities in digital infrastructure (data centers/GPU build-outs) and life sciences driven by wider spreads, stronger documentation and higher forward rates.
OTF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 04, 2026 | 2026 (Q3) | 0.32- | 0.32 | ― | ― |
| Aug 05, 2026 | 2026 (Q2) | 0.300.30 | 0.34 | -11.76% (-0.04) | |
| May 06, 2026 | 2026 (Q1) | 0.310.37 | 0.41 | -9.76% (-0.04) | |
| Feb 18, 2026 | 2025 (Q4) | 0.330.30 | 0.48 | -37.50% (-0.18) | |
| Nov 05, 2025 | 2025 (Q3) | 0.350.32 | 0.57 | -43.86% (-0.25) | |
| Aug 06, 2025 | 2025 (Q2) | 0.330.34 | 0.04 | 750.00% (+0.30) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

